Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT05352815 (COMBINE 1) for Diabetes Mellitus, Type 2 is completed. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Back to Search
Novo Nordisk A/SA Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec (COMBINE 1) Phase 3 1,291 Pregnancy
Clinical Trial NCT05352815 (COMBINE 1) was designed to study Treatment for Diabetes Mellitus, Type 2. This was a Phase 3 interventional study that is now completed. The study started on June 1, 2022, with plans to enroll 1,291 participants. Led by Novo Nordisk A/S, the expected completion date was April 23, 2024. The latest data from ClinicalTrials.gov was last updated on December 4, 2025.
Brief Summary
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin icodec taken once a week in people with type 2 diabetes.
The study will look at how well IcoSema controls blood sugar level in people with type 2 diabetes compared to insulin icodec.
Participants will either get IcoSema or insulin icodec. Which treatment participants get is decid...
Show MoreOfficial Title
A 52 Week Study Comparing the Efficacy and Safety of Once Weekly IcoSema and Once Weekly Insulin Icodec, Both Treatment Arms With or Without Oral Anti Diabetic Drugs, in Participants With Type 2 Diabetes Inadequately Controlled With Daily Basal Insulin.
Conditions
Diabetes Mellitus, Type 2Publications
Scientific articles and research papers published about this clinical trial:Other Study IDs
- COMBINE 1
- NN1535-4591
- U1111-1260-8259 (Other Identifier) (World Health Organization (WHO))
- 2020-005281-34 (EudraCT Number)
NCT ID Number
Start Date (Actual)
2022-06-01
Last Update Posted
2025-12-04
Completion Date (Estimated)
2024-04-23
Enrollment (Estimated)
1,291
Study Type
Interventional
PHASE
Phase 3
Status
Completed
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Parallel
Masking
None (Open Label)
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
ExperimentalIcoSema | IcoSema Participants will receive once weekly IcoSema subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks. |
Active ComparatorInsulin icodec | Insulin icodec Participants will receive once weekly Insulin icodec subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks. |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Change in Glycated Haemoglobin (HbA1c) | Change from baseline (week 0) to week 52 in HbA1c is presented. The outcome measure was evaluated based on the data from in study period, where all data from randomisation until last date of any of the following: 1) last direct participant-site contact; 2) participants who withdrew their informed consent; 3) last participant-investigator contact as defined by the investigator for participants who lost to follow-up (i.e. possibly an unscheduled phone visit); 4) death of participants who died before any of the above. | Baseline (Week 0), Week 52 |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Change in Body Weight | Change from baseline (week 0) to week 52 in body weight is presented. The outcome measure was evaluated based on the data from in study period, where all data from randomisation until last date of any of the following: 1) last direct participant-site contact; 2) participants who withdrew their informed consent; 3) last participant-investigator contact as defined by the investigator for participants who lost to follow-up (i.e. possibly an unscheduled phone visit); 4) death of participants who died before any of the above. | Baseline (Week 0), Week 52 |
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Less Than 3.0 Millimoles Per Litre [mmol/L] (54 Milligram Per Decilitre [mg/dL]), Confirmed by Blood Glucose [BG] Meter) or Severe Hypoglycaemic Episodes (Level 3) | Hypoglycaemic episodes were classified according to the American Diabetes Association/ International Hypoglycaemia Study Group, where glycemic criteria for level 2 was less than (\<) 3.0 mmol/L (54 mg/dL) and level 3 had no specific glucose threshold. The outcome measure was evaluated based on data from on treatment period, where all data from date of first dose of randomised treatment as recorded on the electronic case report form (eCRF) until the first date of any of the following: 1) last follow-up visit ; 2) last date on randomised treatment +6 weeks (corresponding to 5 weeks after the end of the dosing interval for both treatment arms); 3) end-date for the in-study data points sets. | From baseline week 0 to week 57 |
Percentage of Time in Range 3.9-10.0 mmol/L (70-180 mg/dL) Using Continuous Glucose Monitoring (CGM) System, Dexcom G6 | Time in range was defined as 100 times the number of recorded measurements in glycemic range 3.9-10.0 mmol/L (70-180 mg/dL), both inclusive, divided by the total number of recorded measurements. The outcome measure was evaluated based on the data from in study period: Data from randomisation until last date of any of the following: 1) the last direct participant-site contact; 2) withdrawal for participants who withdraw their informed consent; 3) the last participant-investigator contact as defined by the investigator for participants who are lost to follow-up (i.e. possibly an unscheduled phone visit); 4) death for participants who die before any of the above. | From week 48 to week 52 |
Percentage of Time Spent < 3.0 mmol/L (54 mg/dL) Using Continuous Glucose Monitoring (CGM) System, Dexcom G6 | Time spent below threshold was defined as 100 times the number of recorded measurements below the threshold, divided by the total number of recorded measurements. The outcome measure was evaluated based on the data from in study period: Data from randomisation until last date of any of the following: 1) the last direct participant-site contact; 2) withdrawal for participants who withdraw their informed consent; 3) the last participant-investigator contact as defined by the investigator for participants who are lost to follow-up (i.e. possibly an unscheduled phone visit); 4) death for participants who die before any of the above. | From week 48 to week 52 |
Percentage of Time Spent > 10.0 mmol/L (180 mg/dL) Using Continuous Glucose Monitoring (CGM) System, Dexcom G6 | Time spent above threshold is defined as 100 times the number of recorded measurements above the threshold, divided by the total number of recorded measurements. The outcome measure was evaluated based on the data from in study period: Data from randomisation until last date of any of the following: 1) the last direct participant-site contact; 2) withdrawal for participants who withdraw their informed consent; 3) the last participant-investigator contact as defined by the investigator for participants who are lost to follow-up (i.e. possibly an unscheduled phone visit); 4) death for participants who die before any of the above. | From week 48 to week 52 |
Change in Fasting Plasma Glucose (FPG) | Change in FPG from baseline (week 0) to week 52 is presented. The outcome measure was evaluated based on the data from in study period: Data from randomisation until last date of any of the following: 1) the last direct participant-site contact; 2) withdrawal for participants who withdraw their informed consent; 3) the last participant-investigator contact as defined by the investigator for participants who are lost to follow-up (i.e. possibly an unscheduled phone visit); 4) death for participants who die before any of the above. | Baseline (Week 0), Week 52 |
Weekly Basal Insulin Dose | Estimated mean average weekly basal insulin dose from week 50 to week 52 of treatment is presented. The outcome measure was evaluated based on data from on treatment period, where all data from date of first dose of randomised treatment as recorded on the electronic case report form (eCRF) until the first date of any of the following: 1) last follow-up visit (V56); 2) last date on randomised treatment +6 weeks (corresponding to 5 weeks after the end of the dosing interval for both treatment arms); 3) end-date for the in-study data points sets. | From week 50 to week 52 |
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) | Hypoglycaemic episodes were classified according to the American Diabetes Association/ International Hypoglycaemia Study Group, where glycemic criteria for level 2 was less than (\<) 3.0 mmol/L (54 mg/dL). The outcome measure was evaluated based on data from on treatment period, where all data from date of first dose of randomised treatment as recorded on the electronic case report form (eCRF) until the first date of any of the following: 1) last follow-up visit ; 2) last date on randomised treatment +6 weeks (corresponding to 5 weeks after the end of the dosing interval for both treatment arms); 3) end-date for the in-study data points sets. | From baseline week 0 to week 57 |
Number of Severe Hypoglycaemic Episodes (Level 3) | Hypoglycaemic episodes were classified according to the American Diabetes Association/ International Hypoglycaemia Study Group, where glycemic criteria for level 3 had no specific glucose threshold. The outcome measure was evaluated based on data from on treatment period, where all data from date of first dose of randomised treatment as recorded on the electronic case report form (eCRF) until the first date of any of the following: 1) last follow-up visit; 2) last date on randomised treatment +6 weeks (corresponding to 5 weeks after the end of the dosing interval for both treatment arms); 3) end-date for the in-study data points sets. | From baseline week 0 to week 57 |
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
Male or female and age above or equal to 18 years at the time of signing informed consent.
Diagnosed with type 2 diabetes mellitus 180 days or more before screening.
HbA1c of 7.0 10.0% (53.0 85.8 mmol/mol) (both inclusive) as assessed by central laboratory on the day of screening.
Treated with once daily or twice daily basal insulin (neutral protamine hagedorn insulin, insulin degludec, insulin detemir, insulin glargine 100 units/mL, or insulin glargine 300 units/mL) 20- 80 units/day for 90 days or more before screening. Short term bolus insulin treatment for a maximum of 14 days before screening is allowed, as is prior insulin treatment for gestational diabetes. The treatment can be with or without any of the following anti diabetic drugs with stable doses for 90 days or more before screening:
- Metformin
- Sulfonylureas (a)
- Meglitinides (glinides) (a)
- DPP 4 inhibitors (a)
- Sodium glucose co transporter 2 inhibitors
- Alpha glucosidase inhibitors
- Thiazolidinediones
- Marketed oral combination products only including the products listed above.
Body mass index (BMI) below or equal to 40.0 kg/m^2. (a) Sulfonylureas, meglitinides (glinides) and DPP 4 inhibitors must be discontinued at randomisation.
- Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method.
- Anticipated initiation or change in concomitant medication (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or systemic corticosteroids).
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening.
- Any episodes (as declared by the participant or in the medical records.) of diabetic ketoacidosis within 90 days before screening.
- Presence or history of pancreatitis (acute or chronic) within 180 days before screening.
- Any of the following: Myocardial infarction, stroke, hospitalization for unstable angina pectoris or transient ischaemic attack within 180 days before screening.
- Chronic heart failure classified as being in New York Heart Association Class IV at screening.
- Recurrent severe hypoglycaemic episodes within the last year (12 months) as judged by the investigator.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days before screening or in the period between screening and randomisation. Pharmacological pupil dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Novo Nordisk A/S131 active studies to exploreNo contact data.
281 Study Locations in 22 Countries
Arizona
Pri Med Grp dba/Gil Ctr Fam, Gilbert, Arizona, 85296, United States
Lenzmeier Fam Med CCT Research, Glendale, Arizona, 85308, United States
Phoenician Centers for Research & Innovation PCRI, Phoenix, Arizona, 85021, United States
Arkansas
Medical Investigations, Inc., Little Rock, Arkansas, 72211, United States
California
John Muir Physicians Network, Concord, California, 94520, United States
Headlands Research California, LLC, Escondido, California, 92025, United States
Scripps Whittier Diabetes Inst, La Jolla, California, 92037, United States
Clinical Trials Research_Sacramento, Lincoln, California, 95648, United States
Torrance Clin Res Inst, Inc., Lomita, California, 90717, United States
Pacific Clinical Studies, Los Alamitos, California, 90720, United States
Downtown LA Res Ctr. Inc., Los Angeles, California, 90017, United States
Velocity Clin Res Los Angeles, Los Angeles, California, 90017, United States
Valley Clinical Trials, Inc., Northridge, California, 91325, United States
Clinical Trials Research_Sacramento_0, Sacramento, California, 95821, United States
San Diego Family Care, San Diego, California, 92111, United States
NorCal Endocrinology and Internal Medicine, San Ramon, California, 94583, United States
Diablo Clinical Research, Inc., Walnut Creek, California, 94598, United States
Colorado
Creekside Endocrine Associates, PC, Denver, Colorado, 80246, United States
Florida
Clinical Res Of W Florida Inc, Clearwater, Florida, 33765, United States
Northeast Research Institute, Fleming Island, Florida, 32003, United States
University of Miami, Miami, Florida, 33136, United States
Adult Medicine of Lake County, Inc., Mt. Dora, Florida, 32757, United States
Suncoast Clin Res Port Richey, New Port Richey, Florida, 34652, United States
Clinical Neuroscience Solution, Orlando, Florida, 32801, United States
Florida Inst For Clin Res, Orlando, Florida, 32825, United States
Metabolic Research Institute Inc, West Palm Beach, Florida, 33401, United States
Georgia
Javara/Privia Med Grp GA,LLC, Albany, Georgia, 31707, United States
Emory University SOM, Atlanta, Georgia, 30303, United States
Javara Inc., Fayetteville, Georgia, 30214, United States
Physicians Research Assoc. LLC, Lawrenceville, Georgia, 30046, United States
Endocrine Research Solutions, Roswell, Georgia, 30076, United States
Hawaii
East West Med Res Inst, Honolulu, Hawaii, 96814, United States
Idaho
Saltzer Medical Group Research, Nampa, Idaho, 83686-6011, United States
Illinois
UnityPoint Health-Diabetes Care Center, Peoria, Illinois, 61603, United States
Endeavor Health, Skokie, Illinois, 60077, United States
Iowa
Iowa Diab & Endo Res Center, West Des Moines, Iowa, 50266, United States
Kansas
Cotton O'Neil Diab & Endo Ctr, Topeka, Kansas, 66606, United States
Kentucky
The Research Group of Lexington LLC, Lexington, Kentucky, 40503, United States
Louisiana
Barnum Medical Research Inc., Natchitoches, Louisiana, 71457, United States
New Orleans Center for Clinical Research, New Orleans, Louisiana, 70119, United States
Ileana J Tandron APMC, Slidell, Louisiana, 70461-4231, United States
Maryland
MedStar Hlth Res Institute, Hyattsville, Maryland, 20782, United States
Massachusetts
Brigham & Women's Hospital, Boston, Massachusetts, 02115-5804, United States
MassResearch, LLC, Waltham, Massachusetts, 02453, United States
Michigan
Northern Pines Hlth Ctr, PC, Buckley, Michigan, 49620, United States
Elite Research Center, Flint, Michigan, 48532, United States
Minnesota
International Diabetes Center, Minneapolis, Minnesota, 55416, United States
Missouri
StudyMetrix Research LLC, City of Saint Peters, Missouri, 63303, United States
Jefferson City Medical Group, PC, Jefferson City, Missouri, 65109, United States
Nebraska
Methodist Phys. Clinic, Omaha, Nebraska, 68114, United States
University of NE Med Ctr, Omaha, Nebraska, 68198, United States
Nevada
University of Nevada School of Medicine, Las Vegas, Nevada, 89102, United States
Palm Research Center Inc., Las Vegas, Nevada, 89148, United States
New Hampshire
Southern New Hampshire Diabete, Nashua, New Hampshire, 03060, United States
New Jersey
John J Shelmet, MD, Lawrenceville, New Jersey, 08648, United States
New Mexico
Albuquerque Clin Trials, Inc., Albuquerque, New Mexico, 87102, United States
New York
Mid Hudson Medical Research, PLLC, New Windsor, New York, 12553, United States
DiGiovanna Institute for Medical Education & Research, North Massapequa, New York, 11758-1802, United States
Endocrine Associates of Long Island, PC, Smithtown, New York, 11787, United States
SUNY Upstate Medical University, Syracuse, New York, 13210, United States
Southgate Medical Group, LLP, West Seneca, New York, 14224, United States
North Carolina
Javara Inc. / Tryon Medical Partners PLLC, Charlotte, North Carolina, 28287, United States
PharmQuest Life Sciences LLC, Greensboro, North Carolina, 27408, United States
Ohio
Central Ohio Clinical Research LLC, Columbus, Ohio, 43213, United States
Prestige Clinical Research, Franklin, Ohio, 45005, United States
New Venture Medical Research, Wadsworth, Ohio, 44281, United States
Oklahoma
Intend Research, Norman, Oklahoma, 73069, United States
Rhode Island
Care Access, Warwick, Rhode Island, 02886, United States
South Carolina
Palmetto Clinical Research, Summerville, South Carolina, 29485, United States
Tennessee
Athens Medical Group, Athens, Tennessee, 37303, United States
AM Diabetes And Endocrinology Center, Bartlett, Tennessee, 38133, United States
Holston Medical Group_Bristol, Bristol, Tennessee, 37620, United States
Chattanooga Medical Research, LLC, Chattanooga, Tennessee, 37404, United States
Univ Diab & Endo Consultants, Chattanooga, Tennessee, 37411, United States
HealthStar Physicians PC, Morristown, Tennessee, 37813, United States
Texas
Amarillo Med Spec LLP, Amarillo, Texas, 79106, United States
Texas Diabetes & Endocrinology, P.A._Austin, Austin, Texas, 78731, United States
Texas Diabetes & Endocrinology, P.A._Austin, Austin, Texas, 78749, United States
Osvaldo A. Brusco MD PA, Corpus Christi, Texas, 78414, United States
Cedar Research, Dallas, Texas, 75038, United States
Velocity Clinical Res-Dallas, Dallas, Texas, 75230, United States
North Texas Endocrine Center, Dallas, Texas, 75231, United States
Univ of TX SW Med Ctr Dallas, Dallas, Texas, 75390-9302, United States
Diabetes and Thyroid Ctr of FW, Fort Worth, Texas, 76132, United States
PrimeCare Medical Group, Houston, Texas, 77024, United States
Javara Inc. / Privia Medical Group Gulf Coast PLLC, Houston, Texas, 77054, United States
PlanIt Research, PLLC, Houston, Texas, 77079, United States
Protenium Clinical Research, Hurst, Texas, 76054, United States
Medical Colleagues-Texas LLP, Katy, Texas, 77450, United States
Andres Garcia-Zuniga, MD, P.A, Laredo, Texas, 78041, United States
Milton Haber, M.D., Laredo, Texas, 78041, United States
DCOL Ctr for Clin Res, Longview, Texas, 75605, United States
Clinical Investigations Of Texas, Plano, Texas, 75075, United States
Texas Diabetes &Endocrinology, Round Rock, Texas, 78681, United States
Sun Research Institute, San Antonio, Texas, 78215, United States
Briggs Clinical Research, LLC, San Antonio, Texas, 78224, United States
Audie L. Murphy VA Hospital, San Antonio, Texas, 78229, United States
Diabetes & Gladular Disease Research A Cetero Research Co, San Antonio, Texas, 78229, United States
Diabetes Glandular Diseases Clinic, San Antonio, Texas, 78229, United States
Javara Inc Privia Grp Gulf Cst, San Marcos, Texas, 78666, United States
SimCare, PLLC, Sugar Land, Texas, 77478, United States
Sugar Lakes Family Practice PA, Sugar Land, Texas, 77479, United States
Hillcrest Family Health Center, Waco, Texas, 76708, United States
Virginia
Javara Inc. / Privia Medical Group LLC_Appomattox, Appomattox, Virginia, 24522, United States
Javara Inc/Privia Md GpLLC Fst, Forest, Virginia, 24551, United States
Eastern Virginia Medical School, Norfolk, Virginia, 23510, United States
Amherst Family Practice P.C., Winchester, Virginia, 22601, United States
Washington
Sound Medical Research, Port Orchard, Washington, 98366, United States
Rainier Clin Res Ctr Inc, Renton, Washington, 98057, United States
Wisconsin
Ascension Columbia St. Mary's Hospital, Milwaukee, Wisconsin, 53211, United States
Advanced Clinical Research LLC, Bayamón, 00959, Puerto Rico
Manati Ctr For Clin Research, Manatí, 00674, Puerto Rico
Australian Capital Territory
The Canberra Hospital_Garran, Garran, Australian Capital Territory, 2605, Australia
New South Wales
Holdsworth House Clinical Research, Darlinghurst, New South Wales, 2010, Australia
Momentum Clinical Research Darlinghurst, Darlinghurst, New South Wales, 2010, Australia
Novatrials, Kotara, New South Wales, 2289, Australia
Illawarra Diabetes Service Clinical Trials & Research Unit, Wollongong, New South Wales, 2500, Australia
Queensland
Royal Brisbane and Women's Hospital, Herston, Queensland, 4029, Australia
South Australia
Southern Adelaide Diabetes & Endocrine Services, Oaklands Park, South Australia, 5046, Australia
Tasmania
Launceston General Hospital, Launceston, Tasmania, 7250, Australia
Victoria
Barwon Health (The Geelong Hospital), Geelong, Victoria, 3220, Australia
The Alfred Hospital, Melbourne, Victoria, 3004, Australia
Imeldaziekenhuis - Bonheiden - Department of Endocrinology, Bonheiden, 2820, Belgium
UZ Brussel - Universitair Ziekenhuis Brussel, Brussels, 1090, Belgium
Cliniques Universitaires Saint-Luc - Serv Endocrinologie - Diabétologie, Brussels, 1200, Belgium
UZA - UZ Antwerpen - Department of Endocrinology, Edegem, 2650, Belgium
AZ Groeninge - Kortrijk - Centrum Endo - Diabetologie, Kortrijk, 8500, Belgium
CHU Tivoli, La Louvière, 7100, Belgium
UZ Leuven - Endocrinology, Leuven, 3000, Belgium
IPSMC - Dr. Nikolay Kostadinov EOOD, Burgas, 8000, Bulgaria
Medical center Medi City 21 OOD, Kyustendil, 2500, Bulgaria
DCC I- Pleven EOOD Endocrinology, Pleven, 5801, Bulgaria
UMHAT Kaspela EOOD, Endocrinology and Metabolic Diseases Clinic, Plovdiv, 4001, Bulgaria
MMA-MHAT Sofia, Clinic of Endocrinology and Metab. Diseases, Sofia, 1606, Bulgaria
Anhui
Anhui Provincial Hospital-Endocrinology, Hefei, Anhui, 230001, China
Beijing Municipality
Peking University People's Hospital-Endocrinology, Beijing, Beijing Municipality, 100044, China
Chongqing Municipality
Chongqing University Three Gorges Hospital, Chongqing, Chongqing Municipality, 404000, China
Guangdong
Huizhou Central People's Hospital-Endocrinology, Huizhou, Guangdong, 516001, China
Hebei
Harrison International Peace Hospital, Hengshui, Hebei, 053000, China
Hengshui People's Hospital (Harrison International Peace Hospital)-Endocrinology, Hengshui, Hebei, 053000, China
Henan
Huaihe Hospital of Henan University-Endocrinology, Kaifeng, Henan, 475000, China
Jiangsu
Changzhou No.2 People's Hospital, Yanghu Branch, Changzhou, Jiangsu, 213003, China
The First People's Hospital of Changzhou, Changzhou, Jiangsu, 213004, China
The Second Affiliated Hospital of Nanjing Medical University-Endocrinology, Nanjing, Jiangsu, 210011, China
The Second Affiliated Hospital of Nanjing Medical University_Nanjing, Nanjing, Jiangsu, 210011, China
The Second Affiliated Hospital of Soochow University-Endocrinology, Suzhou, Jiangsu, 215004, China
The Affiliated Hospital of Jiangsu University-Endocrinology, Zhenjiang, Jiangsu, 212001, China
Shandong
Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong, 250013, China
Shanghai Municipality
Shanghai Fifth People's Hospital-Endocrinology, Shanghai, Shanghai Municipality, 200240, China
Tianjin Municipality
General Hospital of Tianjin Medical University-Endocrinology, Tianjin, Tianjin Municipality, 300052, China
The Second Hospital of Tianjin Medical University, Tianjin, Tianjin Municipality, 300211, China
City of Zagreb
Poliklinika Solmed, Zagreb, City of Zagreb, 10000, Croatia
County of Osijek-Baranja
Poliklinika SLAVONIJA OSIJEK, Osijek, County of Osijek-Baranja, 31000, Croatia
Klinicki bolnicki centar Osijek, Osijek, 31 000, Croatia
Opca bolnica Pula, Pula, 52100, Croatia
KBC Rijeka, Endokrinologija, Rijeka, 51000, Croatia
Ähtärin terveysasema, Ähtäri, 63700, Finland
Health Step Finland Oy, Kuopio, 70210, Finland
Etelä-Savon sosiaali- ja terveyspalvelujen kuntayhtymä, Mikkeli, 50100, Finland
Raision sosiaali- ja terveyskeskus, Raisio, 21200, Finland
Tampereen diabetesvastaanotto, Tampere, 33900, Finland
Turku University Hospital, Turku, 20520, Finland
Andhra Pradesh
Yashoda Hospital, Secunderabad, Andhra Pradesh, 500003, India
Assam
Apollo Excelcare Hospital, Guwahati, Assam, 781033, India
Gujarat
Gujarat Endocrine Centre, Ahmedabad, Gujarat, 380052, India
Nirmal Hospital Pvt. Ltd., Surat, Gujarat, 395002, India
Karnataka
Lifecare Hospital and Research Centre, Bangalore, Karnataka, 560092, India
Mysore Medical College and Research Institute, Mysore, Karnataka, 570001, India
Kerala
Government Medical College, Kozhikode, Kozhikode, Kerala, 673008, India
Jothydev's Diabetes & Research Center, Thriruvananthapuram, Kerala, 695 032, India
Madhya Pradesh
TOTALL Diabetes Hormone Institute, Indore, Madhya Pradesh, 452010, India
Maharashtra
Excel Endocrine Centre, Kolhāpur, Maharashtra, 416008, India
BYL Nair Hospital and T N Medical College Department of endo, Mumbai, Maharashtra, 400008, India
Seth GS medical college and KEM Hospital, Mumbai, Maharashtra, 400012, India
Bhaktivedanta Hospital & Research Institute, Mumbai, Maharashtra, 401107, India
Inamdar Multispeciality Hospital, Pune, Maharashtra, 411040, India
Odisha
S.C.B. Medical College, Cuttack, Odisha, 753007, India
Punjab
Post Graduate Institute of Medical Education & Research, Chandigarh, Punjab, 160012, India
Dayanand Medical College & Hospital_Ludhiana, Ludhiana, Punjab, 141001, India
Tamil Nadu
M.V.Hospital for Diabetes Pvt. Ltd., Chennai, Tamil Nadu, 600 013, India
Arthur Asirvatham hospital,, Madurai, Tamil Nadu, 625020, India
Telangana
Osmania General Hospital, Hyderabad, Telangana, 500012, India
Ramdev Rao Hospital, Hyderabad, Telangana, 500072, India
Lady Hardinge Medical College, New Delhi, 110001, India
Sir Ganga Ram Hospital, New Delhi, 110060, India
BA
A.O.U. Consorziale Policlinico di Bari, Bari, BA, 70124, Italy
RM
Pol. Uni. Campus Biomedico, Roma, RM, 00128, Italy
Policlinico Mater Domini Università di Catanzaro, Catanzaro, 88100, Italy
ASL 4 Chiavarese, Chiavari (genova), 16043, Italy
Ospedale Policlinico San Martino, Genova, 16132, Italy
Grande Ospedale Metropolitano Niguarda, Milan, 20162, Italy
Fukushima, Japan
Seino Internal Medicine Clinic_Internal medicine, Koriyama-shi, Fukushima, Japan, 963-8851, Japan
Hokkaido, Japan
Manda Memorial Hospital_Internal Medicine, Sapporo-shi, Hokkaido, Hokkaido, Japan, 060-0062, Japan
Kanagawa, Japan
Hayashi Diabetes Clinic, Chigasaki-shi, Kanagawa, Kanagawa, Japan, 253-0044, Japan
Hayashi Diabetes Clinic_Internal Medicine and Diabetes Medicine, Chigasaki-shi, Kanagawa, Japan, 253-0044, Japan
Kumamoto, Japan
Jinnouchi Hospital_Internal Medicine, Kumamoto, Kumamoto, Japan, 862-0976, Japan
Miyazaki
Heiwadai Hospital_Internal Medicine, Miyazaki, Miyazaki, 880-0034, Japan
Heiwadai Hospital, Miyazaki, Miyazaki, 880-0034, Japan
Kumanomae Nishimura Naika Clinic_Internal Medicine, Arakawa-ku, Tokyo, 116-0012, Japan
Akaicho Clinic, Chiba-shi, Chiba, 260-0804, Japan
Futata Tetsuhiro Clinic Meinohama_Internal medicine, Fukuoka-shi, Fukuoka, 819-0006, Japan
Futata Tetsuhiro Clinic Meinohama, Fukuoka-shi, Fukuoka, 819-0006, Japan
Kunisaki Makoto Clinic, Fukuoka-shi, Fukuoka, 819-0168, Japan
Sasaki Internal Medicine, Hokkaido, 062-0007, Japan
Yoshimura clinic, Kumamoto, 861-8039, Japan
Hisatomi Clinic, Saga-shi, Saga, 840-0937, Japan
Tokyo-Eki Center-building Clinic_Internal Medicine, Tokyo, 103-0027, Japan
Fukuwa Clinic_Internal Medicine, Tokyo, 104-0031, Japan
Yokohama City University Hospital, Endocrinology, Metabolism, Yokohama-shi, Kanagawa, 236-0004, Japan
Nuevo León
Hospital Universitario Dr. José Eleuterio González_Monterrey, Monterrey, Nuevo León, 64460, Mexico
Centro de Investigación Cardiometabólica de Aguascalientes, Aguascalientes, 20230, Mexico
Clínicos Asociados BOCM, S.C., Mexico City, 03300, Mexico
Nordlandssykehuset Bodø, Bodø, 8005, Norway
Drammen sykehus - Vestre Viken HF, Drammen, 3004, Norway
Bærum sykehus, Gjettum, 1346, Norway
Sykehuset Innlandet HF Hamar, Hamar, 2318, Norway
Akershus universitetssykehus HF, Lørenskog, 1478, Norway
Oslo universitetssykehus Aker, Oslo, 0586, Norway
St. Olavs Hospital HF, Trondheim, NO-7030, Norway
Lubelski
NZOZ Przychodnia Specjalistyczna Medica, Lublin, Lubelski, 20-538, Poland
Uniwersyteckie Centrum Kliniczne (UCK), Gdansk, 80-214, Poland
NZOZ "CenterMed Lublin" Sp. z o.o., Lublin, 20-044, Poland
Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji, Warsaw, 02-507, Poland
Matosinhos
Unidade Local De Saude De Matosinhos E.P.E., Senhora Da Hora, Matosinhos, Matosinhos, 4464-513, Portugal
Unidade Local De Saude De Almada-Seixal E.P.E. - Hospital Garcia de Orta, Almada, 2805-267, Portugal
Unidade Local De Saude De Amadora Sintra E.P.E. - Hospital Prof. Dr. Fernando da Fonseca, Amadora, 2720-276, Portugal
Unidade Local De Saude Da Regiao De Aveiro E.P.E., Aveiro, 3814-501, Portugal
Unidade de Local de Saúde de Braga, Braga, 4710-243, Portugal
APDP - Associação Protectora dos Diabéticos de Portugal, Lisbon, 1250-189, Portugal
Unidade Local De Saude De Lisboa Ocidental E.P.E. - Hospital Egas Moniz, Lisbon, 1349-019, Portugal
Hospital Da Luz S.A., Lisbon, 1500-650, Portugal
Unidade Local de Saúde de Matosinhos, Matosinhos Municipality, 4464-513, Portugal
Unidade Local de Saúde de Santo António, E.P.E, Porto, 4099-001, Portugal
Hospital Luz Arrabida, S.A., Vila Nova de Gaia, 4400-346, Portugal
Unidade Local De Saude De Tras-Os-Montes E Alto Douro E.P.E., Vila Real, 5000-508, Portugal
Bucurestii
Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila, Bucharest, Bucurestii, 020475, Romania
Maramureş
CMI Diabet, Nutritie, Boli Metabolice "Dr Pop Lavinia", Baia Mare, Maramureş, 430222, Romania
Mariodiab Clinic SRL, Brasov, 500101, Romania
SC Consultmed SRL, Iași, 700547, Romania
Clinica Korall S.R.L. Satu Mare, Satu Mare, 440055, Romania
Spitalul Judetean De Urgenta Sfantul Ioan Cel Nou Suceava, Suceava, 720237, Romania
Russia
Tumen State Medical University, Tyumen, Russia, 625023, Russia
Arkhangelsk Regional Clinical Hospital, Arkhangelsk, 163045, Russia
Irkutsk State Medical Academy of Postgraduate Education, Irkutsk, 664049, Russia
Limited Liability Company "AriVa-Med", Kursk, 305016, Russia
City Consultative & Diagnostic Centre #1, Saint Petersburg, 194354, Russia
Saratov regional clinical hospital, Saratov, 410053, Russia
Sverdlovsk Regional Clinical Hospital #1, Yekaterinburg, 620102, Russia
Endocrinology, Diabetes and Metabolism Diseases Clinic, Belgrade, 11000, Serbia
Gauteng
Deepak Lakha, Johannesburg, Gauteng, 1820, South Africa
Hemant Makan, Johannesburg, Gauteng, 1827, South Africa
Wits Bara Clinical Trial Site, Johannesburg, Gauteng, 2013, South Africa
KwaZulu-Natal
Dr Pillay's Rooms, Durban, KwaZulu-Natal, 4450, South Africa
North West
Armansis Medical Centre, Brits, North West, 0250, South Africa
Western Cape
Langeberg Clinical Trials, Cape Town, Western Cape, 7572, South Africa
Netcare Alberton Hospital, Alberton, 1449, South Africa
Chungcheongnam-do
Soonchunhyang University Hospital, Cheonan, Chungcheongnam-do, 31151, South Korea
Gyeonggi-do
Korea University Ansan Hospital, Ansan, Gyeonggi-do, 15355, South Korea
The Catholic University of Korea, Bucheon ST. Mary's Hospital, Bucheon-si, Gyeonggi-do, 14647, South Korea
Seoul National University Bundang Hospital_Seongnam-si, Seongnam-si, 463-707, South Korea
Korea University Anam Hospital, Seoul, 02841, South Korea
Seoul National University Hospital, Seoul, 03080, South Korea
Kangbuk Samsung Hospital, Seoul, 03181, South Korea
Severance Hospital, Yonsei University Health System, Seoul, 03722, South Korea
Asan Medical Center, Seoul, 05505, South Korea
Seoul Saint Mary's Hospital, Seoul, 06591, South Korea
The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, 06591, South Korea
Nowon Eulji Medical Center, Eulji University, Seoul, 139-827, South Korea
Wonju Severance Christian Hospital, Wŏnju, 26426, South Korea
Changhua Christian Hospital_Metabolic Dept., Changhua, 500, Taiwan
China Medical University Hospital, Taichung, 404, Taiwan
National Cheng Kung University Hospital, Tainan, 704, Taiwan
Chi Mei Medical Center, Tainan, 710, Taiwan
Taipei Medical University Hospital, Taipei, 110, Taiwan
Altindag
Ankara Üniversitesi Tıp Fakültesi İbni Sina Hastanesi-Endokrinoloji, Ankara, Altindag, 06230, Turkey (Türkiye)
Çukurova Üniversitesi Tıp Fakültesi Balcalı Hastanesi- Endokrinoloji, Adana, 01150, Turkey (Türkiye)
Gulhane Egitim Arastirma Hastanesi, Ankara, 06010, Turkey (Türkiye)
Haseki Eğitim ve Araştırma Hastanesi- Dahiliye, Istanbul, 34098, Turkey (Türkiye)
Göztepe Prof. Dr.Süleyman Yalçın Şehir Hastanesi- Dahiliye, Istanbul, 34722, Turkey (Türkiye)
T.C. S.B. Ist Il SagMud Pendik Egitim ve Arastirma Hastanesi, Istanbul, 34899, Turkey (Türkiye)
Tekirdağ Namık Kemal Üniversitesi Hastanesi- Dahiliye, Tekirdağ, 59030, Turkey (Türkiye)